# Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate

> **NCT00083759** · PHASE2 · TERMINATED · sponsor: **Biogen** · enrollment: 299 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** natalizumab
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00083759
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-05
- **Primary completion:** 2005-02
- **Final completion:** —
- **Target enrollment:** 299 (ACTUAL)
- **Why stopped:** The biological effect seen with natalizumab was not sufficient to warrant further development in RA.
- **Last updated:** 2016-07-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00083759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00083759, "Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00083759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*